Edith Wolfson Medical Center
H̱olon, Central District, 5834468, Israel
Location status: Recruiting
NCT Number: NCT07158970
This study evaluates the impact of incorporating home-ultrasound (home-US) devices into telemedicine care for patients with gestational diabetes mellitus (GDM). The study will compare satisfaction, clinical outcomes, and healthcare costs between standard high-risk pregnancy care and care augmented by home-US.
Interested in participating?
Request Info18 year–51 year
Female
Interventional
Not applicable
H̱olon, Central District, 5834468, Israel
Location status: Recruiting
Gestational diabetes mellitus (GDM) requires frequent follow-up to monitor maternal and fetal well-being. While telemedicine improves access and patient satisfaction, it lacks a fetal assessment component. This single-center randomized controlled trial evaluates the integration of home ultrasound (home-US) into telemedicine care for women with GDM.
Participants will be randomized to standard care or an intervention group receiving alternating in-person and telemedicine visits with physician-guided home-US using the Pulsenmore device. The primary outcome is patient satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at term. Secondary outcomes include glycemic control, maternal and neonatal outcomes, healthcare utilization, visit duration, and follow-up costs.
The study will enroll 90 women, aged 18-51, with singleton pregnancies and GDM. The study is conducted at the Edith Wolfson Medical Center in Israel over a one-year period. The home-US device is approved for obstetric use and will be used under real-time physician supervision.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard care
Time frame: at 37-39 weeks gestation
Assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ). It is composed of eight questions, each of which is scored by patients on a scale ranging from zero ("very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient").
The questionnaire is composed of two different factors- the first 6 questions assess treatment satisfaction and the last 2 questions assess burden of hyper or hypo-glycemia. the sum of the first 6 points (maximum 36 points) score the treatment satisfaction, with a higher score indicating higher treatment satisfaction.
Time frame: From enrollment (~24-28 weeks) to 37-39 weeks gestation.
Difference in patient satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) between early pregnancy (after first visit) and late pregnancy (37-39 weeks gestation).
It is composed of eight questions, each of which is scored by patients on a scale ranging from zero ("very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient").
The questionnaire is composed of two different factors- the first 6 questions assess treatment satisfaction and the last 2 questions assess burden of hyper or hypo-glycemia. the sum of the first 6 points (maximum 36 points) score the treatment satisfaction, with a higher score indicating higher treatment satisfaction.
Time frame: From enrollment to delivery.
Assessment of maternal glycemic control based on percent of abnormal glucose values during follow-up (via glucose log or continuous glucose monitoring where available), as recorded by treating physician.
Time frame: At the end of study participation for each patient (between 37-39 weeks gestation).
Clinician satisfaction will be assessed using a structured questionnaire developed for this study. Physicians will rate various aspects of the telemedicine or in-person follow-up experience, including:
Ease of use
Clinical value
Workflow and efficiency
Communication and patient engagement
Technical issues and support
Each domain will be rated on a 10-point numeric rating scale (0-10), where:
0 = Not satisfied at all
10 = Extremely satisfied
Higher scores indicate greater satisfaction.
Time frame: At time of delivery.
Evaluation of mode of delivery (vaginal, cesarean)
Time frame: At time of delivery
Birth weight
Time frame: At 37-39 weeks gestation.
Estimated costs incurred by patients for follow-up (including travel, parking, time off work), collected via structured questionnaire.
Time frame: From enrollment to delivery.
Estimated resource and time costs for the healthcare system based on visit type (in-person vs. telemedicine), calculated per patient.
Time frame: Through study completion, an average of 1 year (from enrollment to delivery for each participant)
Duration of each visit, separately recorded for patient time and physician Duration of each clinical visit will be recorded in minutes for both the patient and the physician. This includes both in-person and telemedicine encounters. Separate timing will be documented for:
Patient time (including waiting and consultation)
Physician time (active interaction and documentation)
These data will be used to compare time efficiency between the two care models.
Time frame: From enrollment to 6 weeks postpartum, confirmed by patient interview and EMR.
Number and reason for unscheduled emergency room visits related to pregnancy or GDM during the study period.
Time frame: collected after birth from data system
Gestational age at birth
Time frame: Within the first 28 days of life
The number of neonates requiring admission to the neonatal intensive care unit (NICU) following delivery will be recorded and reported. This will be used as an indicator of neonatal morbidity.
Contact information is provided by the study sponsor or research team.
Liat Mor
CONTACT
Michal De-Wolf
CONTACT
Wolfson Medical Center
Other Gov
Effect of Home Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04621396
Diabetes Mellitus, Diabetes Mellitus, Type 2
Winnipeg, Manitoba, Canada
View Trial DetailsNCT06445946
Diabetes Mellitus, Diabetes, Gestational
Tuscaloosa, Alabama, United States
View Trial DetailsNCT06436326
Continuous Glucose Monitoring, Diabetes Mellitus
Hsinchu, Taiwan
View Trial DetailsNCT05800509
Depression, Postpartum, Depressive Disorder
Taipei, Taiwan
View Trial Details